| Study | Technique | Sample type | CpGs analysed (PCR‐based tests) | Threshold for methylated | HR (95% confidence interval) | Data source |
| Almuqate 2018 | MS‐RE‐qPCR | NR | NR | > 5% | 4.17 (1.78 to 9.75) | Adjusted HR (for age, sex and surgery) |
| MS‐RE‐qPCR | NR | NR | > 9% | 3.57 (1.67 to 7.62) | Adjusted HR (for age, sex and surgery) | |
| Bady 2012 (E‐GBM) | Bead array | Frozen | 31 and 83 | > 0.358 | 3.28 (1.68 to 6.41) | Unadjusted HR |
| Bead array | Frozen | 78–84 | > 10% | 5.56 (1.25 to 25.0) | Unadjusted HR | |
| PSQ | Frozen | 74–78 | > 7.28% | 2.20 (1.12 to 4.31) | Unadjusted HR | |
| Bady 2012 (M‐GBM) | Bead array | Frozen | 31 and 83 | > 0.358 | 6.46 (2.41 to 17.3) | IPD |
| MSP | NR | 76–80 and 84–86 | NR | 7.21 (2.37 to 22.0) | IPD | |
| Barault 2015 | Methyl‐beaming | FFPE | 79–83 | > 40.2% | 2.78 (1.85 to 5.26) | Unadjusted HR |
| PSQ | FFPE | 76–81 | > 29.6% | 2.63 (1.43 to 4.55) | Unadjusted HR | |
| Barbagallo 2014 | MSP | FFPE | 76–80 and 84–87 | Including weakly | 3.68 (1.66 to 8.18) | KM curves (Fig 3A or 3C, Barbagallo 2014) |
| MSP | FFPE | 76–80 and 84–87 | Excluding weakly | 1.90 (0.72 to 4.99) | KM curves (Fig 3C, Barbagallo 2014) | |
| PSQ | FFPE | NR | > 9% | 3.73 (1.68 to 8.28) | KM curves (Fig 3A or 3B, Barbagallo 2014) | |
| PSQ | FFPE | NR | > 25% | 1.99 (0.92 to 4.32) | KM curves (Fig 3B, Barbagallo 2014) | |
| Bell 2017 | QF‐IHC (AQUA) | FFPE | N/A | > Median | 1.84 (1.38 to 2.43) | Adjusted HR (for age, KPS, resection status and treatment) |
| qMSP | NR | NR | > 8 | 1.77 (1.28 to 2.44) | Adjusted HR (for age, KPS, resection status and treatment) | |
| Brigliadori 2016 | PSQ | FFPE | 74–83 | > 9% | 1.92 (1.17 to 3.14) | KM curves (Fig 1; stratified by extent of resection, Brigliadori 2016) |
| PSQ | FFPE | 74–83 | > 29% | 3.02 (1.72 to 5.29) | KM curves (Fig 2; stratified by extent of resection, Brigliadori 2016) | |
| Chai 2018 (7‐site cohort) | PSQ | Frozen | 72–78 | > 12% | 2.94 (1.12 to 7.69) | Unadjusted HR |
| PSQ | Frozen | 74–78 | > 12% | 2.94 (1.12 to 7.69) | Unadjusted HR | |
| PSQ | Frozen | 75–78 | > 12% | 2.94 (1.12 to 7.69) | Unadjusted HR | |
| Chai 2018 (8‐site cohort) | PSQ | Frozen | 75–78 | > 13% | 2.70 (1.37 to 5.26) | Unadjusted HR |
| PSQ | Frozen | 75–82 | > 12% | 3.03 (1.54 to 6.25) | Unadjusted HR | |
| PSQ | Frozen | 76–79 | > 11% | 2.13 (1.09 to 4.17) | Unadjusted HR | |
| Dahlrot 2018 (NS cohort) | DIF | FFPE | N/A | < 0.2 | 1.60 (0.95 to 2.71) | Unadjusted HR |
| PSQ | FFPE | 74–78 | > 9% | 1.42 (0.84 to 2.40) | Unadjusted HR | |
| Dahlrot 2018 (RSD cohort) | DIF | FFPE | N/A | < 0.2 | 2.00 (1.32 to 3.02) | Unadjusted HR |
| PSQ | FFPE | 74–78 | > 10% | 1.58 (1.14 to 2.19) | KM curves (Fig 3A, Dahlrot 2018) | |
| Dunn 2009 | PSQ | Frozen, smear, FFPE or a combination | 72–83 | > 9% | 3.57 (2.24 to 5.70) | KM curves (Fig 2B, Dunn 2009) |
| PSQ | Frozen, smear, FFPE or a combination | 72–83 | > 20% | 4.25 (2.57 to 7.05) | KM curves (Fig 2D, Dunn 2009) | |
| PSQ | Frozen, smear, FFPE or a combination | 72–83 | > 29% | 4.03 (2.30 to 7.07) | KM curves (Fig 2F, Dunn 2009) | |
| PSQ | Frozen, smear, FFPE or a combination | 72–83 | > 35% | 3.64 (1.99 to 6.67) | KM curves (Fig 2D, Dunn 2009) | |
| PSQ | Frozen, smear, FFPE or a combination | 72–83 | Cluster 1 vs 2 and 3 | 4.44 (2.58 to 7.66) | KM curves (Fig Suppl 4C, Dunn 2009) | |
| PSQ | Frozen, smear, FFPE or a combination | 72–83 | Cluster 1 and 2 vs 3 | 3.59 (2.26 to 5.69) | KM curves (Fig Suppl 4C, Dunn 2009) | |
| Felsberg 2009 | IHC | FFPE | N/A | < 10% | 1.26 (0.70 to 2.25) | KM curves (Fig Suppl 1C, 2nd column, Felsberg 2009) |
| MSP | Frozen (14 FFPE) | NR | NR | 2.23 (1.29 to 3.84) | KM curves (Fig Suppl 1A, 2nd column, Felsberg 2009) | |
| PCR‐mRNA | Frozen (14 FFPE) | N/A | < 50% | 2.66 (0.94 to 7.53) | KM curves (Fig Suppl 1B, 2nd column, Felsberg 2009) | |
| Havik 2012 | MSP | Frozen | 76–80 and 84–87 | NR | 2.02 (1.08 to 3.77) | KM curves (Fig 2A, Johannessen 2018) |
| PCR‐HRM | Frozen | 72–83 | NR | 1.32 (0.64 to 2.68) | KM curves (Fig 2B, Johannessen 2018) | |
| PSQ | Frozen | 74–78 | > 2.68% | 1.85 (1.02 to 3.35) | KM curves (Fig 1B, Havik 2012) | |
| PSQ | Frozen | 74–78 | > 6% | 2.30 (1.21 to 4.38) | Unadjusted HR | |
| PSQ | Frozen | 74–78 | > 7% | 2.33 (1.19 to 4.57) | Unadjusted HR | |
| PSQ | Frozen | 74–78 | > 8% | 2.33 (1.19 to 4.57) | Unadjusted HR | |
| PSQ | Frozen | 74–78 | > 9% | 2.30 (0.99 to 5.33) | Unadjusted HR | |
| PSQ | Frozen | 76–79 | > 6% | 2.30 (1.21 to 4.38) | Unadjusted HR | |
| PSQ | Frozen | 76–79 | > 7% | 2.33 (1.19 to 4.57) | Unadjusted HR | |
| PSQ | Frozen | 76–79 | > 8% | 1.90 (0.99 to 3.65) | Unadjusted HR | |
| PSQ | Frozen | 76–79 | > 9% | 1.90 (0.99 to 3.65) | Unadjusted HR | |
| qMSP | Frozen | 71–73 and 75–86 | NR | 1.72 (0.91 to 3.22) | KM curves (Fig 2C, Johannessen 2018) | |
| qMSP | Frozen | 71–86 | > 0% | 1.66 (0.97 to 2.83) | KM curves (Fig 1A, Havik 2012) | |
| Hsu 2015 | IHC | FFPE | N/A | < 10% | 2.12 (1.32 to 3.42) | Unadjusted HR |
| MSP | FFPE | 76–80 and 84–87 | NR | 2.39 (1.42 to 4.02) | Unadjusted HR | |
| PSQ | FFPE | 76–79 | > 5% | 2.66 (1.49 to 4.76) | Unadjusted HR | |
| qMSP | FFPE | 77–80 and 84–87 | > 0.04% | 2.75 (1.51 to 5.04) | Unadjusted HR | |
| qMSP | FFPE | 77–80 and 84–87 | > 0.1% | 2.83 (1.85 to 4.33) | IPD | |
| Karayan‐Tapon 2010 | IHC | FFPE | N/A | < 15.5% | 1.26 (0.77 to 2.06) | KM curves (Fig 3B, Karayan‐Tapon 2010) |
| MSP | Frozen | 76–80 and 84–87 | NR | 2.32 (1.39 to 3.87) | KM curves (Fig 1A, Karayan‐Tapon 2010) | |
| PCR‐mRNA | Frozen | N/A | < 0.39 | 1.68 (1.04 to 2.73) | KM curves (Fig 3A, Karayan‐Tapon 2010) | |
| PSQ | Frozen | 74 | > 5.5% | 3.26 (1.91 to 5.59) | KM curves (Fig Elec Suppl 1B, Karayan‐Tapon 2010) | |
| PSQ | Frozen | 74–78 | > 8.0% | 3.35 (1.95 to 5.73) | KM curves (Fig 2B; cpg mean, Karayan‐Tapon 2010) | |
| PSQ | Frozen | 75 | > 8.7% | 3.26 (1.91 to 5.57) | KM curves (Fig Elec Suppl 1B, Karayan‐Tapon 2010) | |
| PSQ | Frozen | 76 | > 8.0% | 2.78 (1.64 to 4.74) | KM curves (Fig Elec Suppl 1B, Karayan‐Tapon 2010) | |
| PSQ | Frozen | 77 | > 7.85% | 3.65 (2.10 to 6.34) | KM curves (Fig 2B, Karayan‐Tapon 2010) | |
| PSQ | Frozen | 78 | > 7.8% | 2.70 (1.59 to 4.58) | KM curves (Fig Elec Suppl 1B, Karayan‐Tapon 2010) | |
| SQ‐MSP | Frozen | 76–80 and 84–87 | > 35 | 2.75 (1.66 to 4.53) | KM curves (Fig 1B, Karayan‐Tapon 2010) | |
| Kim 2016 | MSP | FFPE | 76–80 and 84–87 | NR | 7.66 (2.82 to 20.8) | KM curves (Fig 2G, Kim 2016) |
| PSQ | FFPE | 74–78 | > 9% | 7.66 (2.82 to 20.8) | KM curves (Fig 2G, Kim 2016) | |
| Kristensen 2016 | IHC | FFPE | N/A | At 0% | 1.58 (1.12 to 2.22) | Unadjusted HR |
| PSQ | Frozen | NR | > 10% | 1.80 (1.23 to 2.62) | Unadjusted HR | |
| qMSP‐PSQ | Frozen | NR | > 0.1% | 1.64 (1.15 to 2.33) | Unadjusted HR | |
| qMSP‐PSQ | Frozen | NR | > 5% | 1.66 (1.02 to 2.71) | KM curves (Fig 5a, Kristensen 2016) | |
| qMSP‐PSQ | Frozen | NR | > 20% | 1.52 (0.77 to 3.00) | KM curves (Fig 5a, Kristensen 2016) | |
| Lalezari 2013 | IHC | FFPE | N/A | < 30% | 1.74 (1.39 to 2.16) | KM curves (Fig 1A, Lalezari 2013) |
| MSP | FFPE | 76–80 and 84–87 | NR | 2.13 (1.67 to 2.78) | Adjusted HR (for age, sex, KPS, extent of resection, bevacizumab treatment at any time and IDH1R132 mutation status) | |
| PSQ | FFPE | 72–95 | NR | 2.06 (1.62 to 2.62) | KM curves (Fig 1E; unadjusted, Lalezari 2013) | |
| Lattanzio 2015 | MSP | FFPE | 76–80 and 84–87 | NR | 1.45 (0.76 to 2.76) | KM curves (Fig 3B, Lattanzio 2015) |
| MSP | Frozen | 76–80 and 84–87 | NR | 2.27 (1.21 to 4.26) | KM curves (Fig 3A, Lattanzio 2015) | |
| PSQ | FFPE | 72–80 | ≥ 9% | 2.09 (1.09 to 3.99) | KM curves (Fig 3D, Lattanzio 2015) | |
| PSQ | Frozen | 72–80 | ≥ 9% | 2.25 (1.19 to 4.25) | KM curves (Fig 3C, Lattanzio 2015) | |
| Lechapt‐Zalcman 2012 | IHC | FFPE | N/A | < 15% | 1.99 (1.15 to 3.42) | KM curves (Fig 4d; unadjusted, Lechapt‐Zalcman 2012) |
| MSP | FFPE | 76–80 and 84–87 | NR | 1.78 (1.03 to 3.09) | KM curves (Fig 4c; unadjusted, Lechapt‐Zalcman 2012) | |
| McDonald 2013 | MSP | FFPE | 76–80 | NR | 1.64 (0.95 to 2.83) | IPD |
| PSQ | FFPE | 74–78 | > 8% | 1.96 (1.16 to 3.33) | Unadjusted HR | |
| Melguizo 2012 | IHC | FFPE | N/A | < 25% | 1.11 (0.69 to 1.77) | KM curves (Fig 4B, Melguizo 2012) |
| MSP | NR | 76–80 and 84–87 | NR | 1.77 (1.06 to 2.95) | KM curves (Fig 4A, Melguizo 2012) | |
| Nguyen 2015 | FSQ‐MS‐PCR | Frozen or FFPE | 76–80 and 84–87 | > 15% | 2.68 (1.70 to 4.21) | KM curves (Fig 3D, Nguyen 2015) |
| FSQ‐MS‐PCR | Frozen or FFPE | 76–80 and 84–87 | > 60% | 2.25 (1.31 to 3.87) | KM curves (Fig 3D, Nguyen 2015) | |
| Park 2011 | MS‐MLPA | 50% frozen and 50% FFPE | NR | > 0.1% | 2.38 (1.11 to 5.10) | KM curves (Fig 2B, Park 2011) |
| MS‐MLPA | 50% frozen and 50% FFPE | NR | > 0.2 | 1.88 (0.86 to 4.11) | KM curves (Fig 2B, Park 2011) | |
| MSP | 50% frozen and 50% FFPE | 76–80 and 84–86 | NR | 4.53 (1.58 to 12.9) | KM curves (Fig 2A, Park 2011) | |
| Quillien 2014 (test) | IHC | FFPE | N/A | < 23% | 2.33 (1.44 to 3.74) | Adjusted HR (for age and KPS) |
| MSP | Frozen | 76–80 and 84–87 | NR | 2.70 (1.65 to 4.43) | Adjusted HR (for age and KPS) | |
| MethyLight‐MSP | Frozen | 75–86 | > 0 | 1.67 (1.00 to 2.77) | Adjusted HR (for age and KPS) | |
| PCR‐HRM | Frozen | 70–83 | > 50% | 1.92 (1.12 to 3.29) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 74 | > 4% | 2.44 (1.51 to 3.95) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 74 | > 8% | 2.22 (1.30 to 3.79) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 74–78 | > 8% | 3.13 (1.86 to 5.25) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 74–78 | > 9% | 3.13 (1.81 to 5.38) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 74–89 | > 11% | 3.13 (1.84 to 5.30) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 75 | > 11% | 3.23 (1.87 to 5.55) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 75–79 | > 8% | 2.94 (1.71 to 5.06) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 76 | > 4% | 2.63 (1.61 to 4.31) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 76 | > 5% | 2.78 (1.62 to 4.75) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 76–79 | > 8% | 2.86 (1.66 to 4.92) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 76–80 | > 9% | 3.03 (1.74 to 5.26) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 77 | > 6% | 3.13 (1.87 to 5.23) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 77 | > 7% | 2.78 (1.63 to 4.74) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 77–81 | > 8% | 2.70 (1.59 to 4.59) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 78 | > 4% | 2.33 (1.38 to 3.92) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 78 | > 5% | 2.50 (1.51 to 4.13) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 78–82 | > 9% | 2.86 (1.68 to 4.86) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 79 | > 7% | 2.78 (1.61 to 4.80) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 79–83 | > 8% | 2.86 (1.68 to 4.86) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 80 | > 4% | 2.56 (1.54 to 4.28) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 81 | > 8% | 2.44 (1.44 to 4.14) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 82 | > 16% | 2.94 (1.70 to 5.08) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 83 | > 10% | 2.78 (1.65 to 4.66) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 84 | > 9% | 3.23 (1.86 to 5.59) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 84–88 | > 17% | 3.23 (1.86 to 5.58) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 84–89 | > 22% | 3.23 (1.85 to 5.62) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 85 | > 5% | 2.50 (1.52 to 4.11) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 85–89 | > 13% | 2.94 (1.76 to 4.92) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 86 | > 11% | 2.78 (1.65 to 4.69) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 87 | > 25% | 3.03 (1.75 to 5.24) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 88 | > 4% | 2.27 (1.38 to 3.75) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 89 | > 12% | 3.23 (1.91 to 5.46) | Adjusted HR (for age and KPS) | |
| Quillien 2014 (validation) | PSQ | FFPE | 74–78 | > 9% | 3.70 (1.71 to 8.01) | Unadjusted HR |
| PSQ | FFPE | 74–78 | > 10% | 2.86 (1.42 to 5.74) | Unadjusted HR | |
| PSQ | FFPE | 74–78 | > 28% | 2.27 (0.98 to 5.29) | Unadjusted HR | |
| Quillien 2016 | PSQ | FFPE | 74–78 | > 6% | 3.23 (2.02 to 5.16) | Adjusted HR (for age and KPS) |
| PSQ | FFPE | 74–78 | > 8% | 4.00 (2.30 to 6.97) | Adjusted HR (for age and KPS) | |
| PSQ | FFPE | 74–78 | > 12% | 4.17 (2.35 to 7.38) | Adjusted HR (for age and KPS) | |
| PSQ | FFPE | 74–78 | > 13% | 4.35 (2.41 to 7.83) | Adjusted HR (for age and KPS) | |
| PSQ | FFPE | 74–78 | > 16% | 4.55 (2.48 to 8.34) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 74–78 | > 6% | 4.00 (2.30 to 6.97) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 74–78 | > 8% | 3.57 (2.14 to 5.95) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 74–78 | > 12% or 13% | 3.45 (2.10 to 5.66) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 74–78 | > 12% | 3.70 (2.19 to 6.26) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 74–78 | > 16% | 3.13 (1.94 to 5.04) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 76–79 | > 8% | 3.33 (2.06 to 5.40) | Adjusted HR (for age and KPS) | |
| PSQ | Frozen | 76–79 | > 12% | 3.33 (2.06 to 5.40) | Adjusted HR (for age and KPS) | |
| SQ‐MSP | FFPE | 76–80 and 84–87 | > 12% | 3.33 (2.06 to 5.40) | Adjusted HR (for age and KPS) | |
| SQ‐MSP | FFPE | 76–80 and 84–87 | > 13% | 3.33 (2.06 to 5.40) | Adjusted HR (for age and KPS) | |
| SQ‐MSP | FFPE | 76–80 and 84–87 | > 23% | 4.17 (2.35 to 7.38) | Adjusted HR (for age and KPS) | |
| SQ‐MSP | Frozen | 76–80 and 84–87 | > 13% | 2.86 (1.79 to 4.57) | Adjusted HR (for age and KPS) | |
| SQ‐MSP | Frozen | 76–80 and 84–87 | > 23% | 2.17 (1.38 to 3.44) | Adjusted HR (for age and KPS) | |
| Thon 2017 | MSP | Frozen | 76–80 and 84–87 | NR | 3.33 (1.82 to 6.25) | Unadjusted HR |
| Sequencing | Frozen | 75–99 (unclear) | > 50% | 3.33 (1.82 to 6.25) | Unadjusted HR | |
| Yamashita 2018 | MSP | Frozen | 76–80 and 84–87 | NR | 2.36 (1.62 to 5.05) | Unadjusted HR |
| PCR‐HRM | Frozen | 72–89 | > 5% | 2.36 (1.43 to 3.90) | KM curves (Fig Suppl 13, Yamashita 2018) | |
| PCR‐HRM | Frozen | 72–89 | > 8% | 2.05 (1.24 to 3.39) | KM curves (Fig Suppl 13, Yamashita 2018) | |
| PCR‐HRM | Frozen | 72–89 | > 10% | 2.51 (1.63 to 4.83) | Unadjusted HR | |
| PCR‐HRM | Frozen | 72–89 | > 12% | 2.61 (1.54 to 4.42) | KM curves (Fig Suppl 13, Yamashita 2018) | |
| PCR‐HRM | Frozen | 72–89 | > 15% | 2.39 (1.41 to 4.05) | KM curves (Fig Suppl 13, Yamashita 2018) | |
| Yang 2012 | IHC | FFPE | N/A | < 10% | 1.07 (0.35 to 3.31) | IPD |
| MSP | FFPE | 76–80 and 84–87 | NR | 1.35 (0.44 to 4.16) | IPD | |
| Yoshioka 2018 | SQ‐MSP | Frozen | 76–80 and 84–87 | > 0 | 2.72 (1.28 to 5.74) | KM curves (Fig 2A, Yoshioka 2018) |
| SQ‐MSP | Frozen | 76–80 and 84–87 | > 2 | 2.18 (1.20 to 3.97) | KM curves (Fig 2B, Yoshioka 2018) | |
| SQ‐MSP | Frozen | 76–80 and 84–87 | > 4 | 1.85 (1.07 to 3.18) | KM curves (Fig 2C, Yoshioka 2018) | |
| SQ‐MSP | Frozen | 76–80 and 84–87 | > 6 | 1.83 (1.10 to 3.04) | KM curves (Fig 2D, Yoshioka 2018) | |
| SQ‐MSP | Frozen | 76–80 and 84–87 | > 8 | 1.71 (1.00 to 2.93) | KM curves (Fig 2E, Yoshioka 2018) | |
| CpG: 5'‐cytosine‐phosphate‐guanine‐3'; DIF: double immunofluorescence; FFPE: formalin‐fixed paraffin‐embedded; FSQ‐MS‐PCR: fluorescent semi‐quantitative methylation‐specific polymerase chain reaction; HR: hazard ratio; IDH: isocitrate dehydrogenase; IHC: immunohistochemistry; IPD: individual participant data; KM: Kaplan‐Meier; KPS: Karnofsky performance status; MS‐MLPA: methylation‐specific multiplex ligation‐dependent probe amplification; MS‐RE‐qPCR: methylation‐specific restriction enzyme quantitative polymerase chain reaction; MSP: methylation‐specific polymerase chain reaction; N/A: not applicable; NR: not reported; PCR: polymerase chain reaction; PCR‐HRM: polymerase chain reaction with high‐resolution melting; PCR‐mRNA: polymerase chain reaction‐messenger ribonucleic acid; PSQ: pyrosequencing; QF‐IHC: quantitative fluorescence immunohistochemistry; qMSP: quantitative methylation‐specific polymerase chain reaction; qMSP‐PSQ: quantitative methylation‐specific polymerase chain reaction with pyrosequencing; SQ‐MSP: semi‐quantitative methylation‐specific polymerase chain reaction. | ||||||
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.